We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was down 1.02% at $63.75. The stock fell short of the S&P 500, which registered a loss of 0.59% for the day. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq depreciated by 0.65%.
Coming into today, shares of the biopharmaceutical company had gained 1.11% in the past month. In that same time, the Medical sector lost 0.36%, while the S&P 500 lost 1.37%.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.68, showcasing a 3.07% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $12.46 billion, up 1.93% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.86 per share and revenue of $49.82 billion, indicating changes of +11.54% and +3.38%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.15% decrease. Currently, Bristol Myers Squibb is carrying a Zacks Rank of #3 (Hold).
Digging into valuation, Bristol Myers Squibb currently has a Forward P/E ratio of 9.39. This expresses a discount compared to the average Forward P/E of 20.54 of its industry.
We can also see that BMY currently has a PEG ratio of 0.31. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.9 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was down 1.02% at $63.75. The stock fell short of the S&P 500, which registered a loss of 0.59% for the day. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq depreciated by 0.65%.
Coming into today, shares of the biopharmaceutical company had gained 1.11% in the past month. In that same time, the Medical sector lost 0.36%, while the S&P 500 lost 1.37%.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.68, showcasing a 3.07% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $12.46 billion, up 1.93% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.86 per share and revenue of $49.82 billion, indicating changes of +11.54% and +3.38%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.15% decrease. Currently, Bristol Myers Squibb is carrying a Zacks Rank of #3 (Hold).
Digging into valuation, Bristol Myers Squibb currently has a Forward P/E ratio of 9.39. This expresses a discount compared to the average Forward P/E of 20.54 of its industry.
We can also see that BMY currently has a PEG ratio of 0.31. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.9 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.